|
|
 |
|
Viewing report
|
|
|
|
Monoclonal Antibodies In Asthma: The Choice Between Life And Breath?
Datamonitor, Feb 2006, Pages: 49
Although only 5% of asthma suffers have severe asthma, these patients account for a disproportionately high percentage of healthcare spending, as asthma-related hospitalizations and emergency room visits are two of the costliest outcomes, which highlights the significant unmet need in this market.
Scope of this title:
- Evaluation of the market potential and dynamics of Xolair, currently the only marketed respiratory monoclonal antibody
- Examination of the key mediators in asthma and the evidence supporting their role
- Identification and evaluation of fifteen monoclonal antibodies currently in preclinical or clinical development to treat asthma
- Assessment of drivers and resistors of using monoclonal antibodies in the severe asthma market
Highlights of this title:
Xolair is set to dominate the respiratory monoclonal antibody market through to 2010, and data from the TENOR study may help Genentech and Novartis to further increase market penetration if a role for IgE in non-atopic asthma is identified.
Th2 mediators are the target of most respiratory monoclonal antibody programs, of which IL-13 is generating the greatest interest, with one third of programs targeting this mediator.
Although there is a significant unmet need among severe asthma patients who are non-responsive to corticosteroids, the price point of respiratory monoclonal antibodies will limit penetration in cost-conscious Europe, transforming the US into the dominant revenue-creation market.
Reasons to order your copy:
- Evaluate the current state of the monoclonal antibodies market and the market capture potential for these products in severe asthma
- Assess the key technological trends to capitalize on opportunities in the respiratory monoclonal antibody sector
- Identify possible targets to focus monoclonal antibody design
Customers who bought this item also bought
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Stakeholder Opinions: Asthma Phenotypes A Changing Paradigm
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
European Asthma Therapeutics Markets
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Asthma And COPD - Get Smart
Monoclonal Antibodies Report Part I
U.S. Asthma Therapeutics Market
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
Monoclonal Antibodies Report: 2008 Update
Asthma Therapeutics: New Treatment Options and Emerging Drug Discovery Targets
Pipeline Insight: Asthma/COPD/Allergic Rhinitis - As Patents Expire, Novel Combinations Inspire
|
|
|
|
